CADILA HEALTHCARE LIMITED Patent applications |
Patent application number | Title | Published |
20160136131 | FORMULA COMPRISING A HYPOLIPIDEMIC AGENT - The present invention relates to the stable pharmaceutical composition of a suitable hypolipidemic agent. Preferably, the present invention discloses novel formulations of the compound of formula (I), or pharmaceutically acceptable salts of compounds of formula (I). More particularly the present invention relates to the stable pharmaceutical composition of compounds of formula (I) comprising compounds of formula (I) or its pharmaceutically acceptable salts, wherein the pH of the formulation is maintained above 7. | 05-19-2016 |
20160107989 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES - The present invention provides pyrroles having hypolipidemic hypocholesteremic activities. The invention provides saroglitazar and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also provides a process for the preparation of saroglitazar. The invention further provides intermediates as well process for preparation thereof. | 04-21-2016 |
20160083345 | POLYMORPHIC FORMS OF LOMITAPIDE AND ITS SALTS AND PROCESSES FOR THEIR PREPARATION - The present invention relates to various polymorphic forms of lomitapide or its salts and processes for preparation thereof. The present invention provides Lomitapide mesylate in solid amorphous form and process for preparation thereof. The invention also provides an amorphous solid dispersion of lomitapide mesylate. Further, various crystalline forms of lomitapide mesylate like A, B and C and process for preparation thereof are provided. The invention also provides crystalline forms of lomitapide free base, in particular Form I and Form-II and their preparation. The invention further provides compositions comprising various forms of lomitapide and its salts. | 03-24-2016 |
20160068484 | SYNERGISTIC COMPOSITIONS - The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) | 03-10-2016 |
20160058730 | PHARMACEUTICAL COMPOSITIONS OF TERIFLUNOMIDE - The present invention relates to stable pharmaceutical compositions of teriflunomide or a pharmaceutically acceptable salt thereof. In particular, the invention relates to the stable pharmaceutical compositions of teriflunomide or a pharmaceutically acceptable salt thereof with colloidal silicon dioxide. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of relapsing forms of multiple sclerosis. | 03-03-2016 |
20160022604 | DIRECTLY COMPRESSED OSPEMIFENE COMPOSITIONS - The present invention relates to pharmaceutical compositions comprising ospemifene or a pharmaceutically acceptable salt thereof prepared by direct compression process. The compositions of the invention may be advantageously used for the treatment or prevention of atrophy-related diseases or disorders in women, especially in women during or after the menopause. | 01-28-2016 |
20160002275 | PROCESS FOR PREPARATION AND PURIFICATION OF CANAGLIFLOZIN - The present invention provides a canagliflozin complex. The complex is provided with an adsorbent selected from activated carbon, silica gel, ionic or non-ionic polymer and a cyclodextrin or derivatives thereof. The invention also provides a process for the preparation of canagliflozin and its intermediates thereof. The invention further provides a process for the purification of canagliflozin. | 01-07-2016 |
20160000732 | ORAL PHARMACEUTICAL COMPOSITIONS OF OSPEMIFENE - The present invention relates to pharmaceutical compositions comprising ospemifene or a pharmaceutically acceptable salt thereof having an average particle size of more than 20 microns and one or more pharmaceutically acceptable excipients comprising at least one solubility enhancing agent. The compositions of the invention may be advantageously used for the treatment or prevention of atrophy-related diseases or disorders in women, especially in women during or after the menopause. | 01-07-2016 |
20160000654 | METHOD FOR DETERMINING FORMULATION ORIENTATION OF ASYMMETRIC MULTI-LAYERED OSMOTIC TABLETS - The present invention relates to a method for preparing asymmetric multi-layered osmotic tablets using rapid and accurate determination of the orientation of tablets with respect to different internal formulation layers proximate to the opposite curved surfaces. In particular, the invention relates to detect degree of curvature using an image recognition system and drill the desired surface using a laser beam. | 01-07-2016 |
20150307540 | AMORPHOUS FORM OF DAPAGLIFLOZIN 1,2-PROPANEDIOL - The invention provides an amorphous form of dapagliflozin 1,2-propanediol of Formula (A) or hydrates thereof and their process for preparation. The present invention also provides a pharmaceutical composition comprising art amorphous solid dispersion containing dapagliflozin 1,2-propanediol or hydrates thereof. | 10-29-2015 |
20150299193 | NOVEL QUINOLONE DERIVATIVES - The present invention relates to novel compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. | 10-22-2015 |
20150283249 | AMORPHOUS FORM OF APREMILAST - The present invention provides an amorphous form of apremilast and process for preparation thereof. The present invention also provides a pharmaceutical composition comprising an amorphous apremilast and one or more of pharmaceutically acceptable carriers, excipients or diluents used for the treatment of active psoriatic arthritis. | 10-08-2015 |
20150283068 | STABLE ORALLY DISINTEGRATING TABLETS OF HYOSCYAMINE - The present invention relates to stable orally disintegrating tablets of hyoscyamine or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such tablets and use thereof. | 10-08-2015 |
20150231081 | DELAYED RELEASE POSACONAZOLE TABLETS - The present invention relates to a delayed release composition comprising Posaconazole dissolved or molecularly dispersed in a polymer other than a hydroxypropyl methylcellulose derived polymer; wherein the composition is prepared by hot melt extruding an admixture of Posaconazole and the polymer. The present invention also provides a process of preparing said composition. | 08-20-2015 |
20150202149 | PHARMACEUTICAL COMPOSITIONS OF MESALAMINE SUPPOSITORIES - The present invention relates to pharmaceutical compositions of mesalamine suppositories. In particular, the invention relates to pharmaceutical suppositories comprising mesalamine or salts thereof and at least two oily or fatty bases. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of ulcerative colitis or ulcerative proctitis. | 07-23-2015 |
20150099696 | NOVEL COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES - The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The present invention is directed to compounds suitable for the treatment of Disease conditions such as hyperlipidemia. | 04-09-2015 |
20150087834 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN PHOSPHATE - The present invention relates to a method for the preparation of sitagliptin phosphate and sitagliptin phosphate anhydrous of Formula (I′) and monohydrate of Formula (I), | 03-26-2015 |
20150072014 | Pharmaceutical Compositions of Sodium Picosulfate, Magnesium Oxide and Citric Acid - The present invention relates to pharmaceutical compositions of sodium picosulfate, magnesium oxide and citric acid. In particular, the invention relates to pharmaceutical compositions comprise granules having a layer of sodium picosulfate on neutral carrier/s. The invention also relates to processes for the preparation of such compositions and use thereof for bowel cleansing. | 03-12-2015 |
20150071936 | PHARMACEUTICAL FORMULATIONS OF TNF-ALPHA ANTIBODIES - The present invention provides certain improved formulations of proteins. Specifically, the present invention provides use of certain excipients that are useful for stabilization of antibody preparations. Additionally, the novel formulations of the present invention prevents the formation of aggregates or fragments or modifications of protein in solution. | 03-12-2015 |
20150071876 | COMBINED MEASLES-MALARIA VACCINE - A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several | 03-12-2015 |
20150064254 | METHOD FOR TREATMENT OF PAIN AND INFLAMMATION - The present invention relates to a method for the treatment of pain and inflammation. In particular, the present invention relates to a method for the treatment of musculo-skeletal and connective tissue pain/inflammations. Further, the invention relates to reducing the incidence and seventy of adverse events resulting from administration of diclofenac. The method comprises administration of a topical pharmaceutical composition of diclofenac or its salts. | 03-05-2015 |
20150051228 | AMORPHOUS FORM OF LINAGLIPTIN AND PROCESS FOR PREPARATION THEREOF - The present invention relates to an amorphous form of linagliptin and processes for the preparation thereof. The invention also relates to a pharmaceutical composition comprising therapeutically effective amount of an amorphous form of linagliptin and use of said composition for treatment of diabetes especially type-I or type-II, prediabetes or reduction of glucose tolerance. | 02-19-2015 |
20150011589 | PROCESS FOR THE PREPARATION OF DABIGATRAN ETEXILATE MESYLATE AND POLYMORPHS OF INTERMEDIATES THEREOF - The present invention provides crystalline form of intermediates of Formula 2A, | 01-08-2015 |
20140378682 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN - The invention discloses processes for the preparation of rivaroxaban and its pharmaceutically acceptable salts, solvates, and hydrates thereof. The invention also relates to novel intermediates for the preparation of rivaroxaban. | 12-25-2014 |
20140348931 | SUSTAINED-RELEASE TOPIRAMATE FORMULATIONS - The present invention relates to a sustained release pharmaceutical formulation comprising topiramate and one or more pharmaceutically acceptable excipients, wherein the formulation comprises two extended release (XR) components or a combination of an extended release (XR) component and immediate release (IR) component, wherein at least one component is in a matrix form. It also relates to method of preparing such formulations and using those formulations in the treatment of neurological and/or psychiatric condition. | 11-27-2014 |
20140348909 | PHARMACEUTICAL COMPOSITIONS OF LURASIDONE - The present invention relates to pharmaceutical compositions of lurasidone or salts thereof. In particular, the invention relates to pharmaceutical compositions of lurasidone or salts thereof with one or more water-insoluble pharmaceutical excipients. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of schizophrenia, bipolar disorders or senile dementia. | 11-27-2014 |
20140343076 | PHARMACEUTICAL COMPOSITIONS OF LURASIDONE - The present invention relates to pharmaceutical compositions of lurasidone or salts thereof. In particular, the invention relates to pharmaceutical compositions of lurasidone or salts thereof with one or more acids. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of schizophrenia, bipolar disorders or senile dementia. | 11-20-2014 |
20140343073 | PROCESS FOR PREPARATION OF AMORPHOUS FORM OF DASATINIB - A stable amorphous form of dasatinib of Formula (I) wherein amorphous dasatinib after exposure to a relative humidity of 75% at 40° C. or 60% at 25° C. for a period of at least three months doesn't change to crystalline form and a process for the preparation of the amorphous form of dasatinib of Formula (I). | 11-20-2014 |
20140296572 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF - The invention relates to improved processes for the preparation of lacosamide. The invention also relates to a novel intermediate useful in the preparation of lacosamide. The invention also relates to process for the purification of lacosamide. | 10-02-2014 |
20140243383 | PHARMACEUTICAL COMPOSITIONS OF SILODOSIN - The present invention discloses a stable pharmaceutical composition comprising: (a) plurality of granules comprising silodosin or salts thereof and one or more pharmaceutical excipients; and (b) an extragranular portion comprising one or more lubricants and optionally one or more surfactants, wherein the granules are free of partially pregelatinized starch. | 08-28-2014 |
20140199401 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF FESOTERODINE - A stable extend release pharmaceutical composition is disclosed. The composition comprises particles of fesoterodine or salts thereof, one or more rate controlling polymers and one or more pharmaceutically acceptable excipients wherein at least 90% of the total amount of particles of fesoterodine or salts thereof by volume (D | 07-17-2014 |
20140199382 | STABLE PHARMACEUTICAL COMPOSITIONS OF AN S1P RECEPTOR AGONIST - The present invention relates to a stable pharmaceutical composition comprising an S1P receptor agonist and one or more pharmaceutically acceptable excipients, wherein the composition is free of a sugar alcohol. It also relates to method of preparing such compositions and using those compositions in the treatment of multiple sclerosis. | 07-17-2014 |
20140148593 | PROCESS FOR PREPARING FLUTICASONE PROPIONATE/FUROATE - The present invention relates to an improved process for the preparation of substituted Fluticasone derivatives. The invention also reveals the processes for the purification of Fluticasones and related intermediates to provide the highly pure product. | 05-29-2014 |
20140148481 | PITAVASTATIN CALCIUM AND PROCESS FOR ITS PREPARATION - The invention provides the process for the preparation of pitavastatin and its pharmaceutically acceptable salts thereof. In particular, the invention provides a process for the preparation of stable pitavastatin calcium in crystalline form having water content less than 5% wt/wt. The present invention also provides stable crystalline form of pitavastatin calcium substantially free from crystal Form-A and use thereof for pharmaceutical compositions. | 05-29-2014 |
20140147896 | ENZYME FOR THE PRODUCTION OF OPTICALLY PURE 3-QUINUCLIDINOL - The present invention provides a process for production of optically pure quinuclidinol of formula-(I) by reduction of quinuclidinone of formula-(II) in presence of suitable oxidoreductase enzyme derived from | 05-29-2014 |
20140121373 | PROCESS FOR PREPARING STABLE POLYMORPHIC FORM OF ERLOTINIB HYDROCHLORIDE - The present invention discloses an improved and efficient process for preparing Erlotinib hydrochloride suitable as a cancer drug. | 05-01-2014 |
20140121215 | PROCESS FOR THE PREPARATION OF AMORPHOUS IMATINIB MESYLATE - The field of the invention relates to a process for the preparation of amorphous imatinib mesylate. In particular, the invention relates to a process for the preparation of stable amorphous imatinib mesylate. More particularly, the invention relates to pharmaceutical compositions that includes the stable amorphous imatinib mesylate together along with its excipients. | 05-01-2014 |
20140113942 | PROCESS FOR THE PREPARATION AND PURIFICATION OF AZILSARTAN MEDOXOMIL - The present invention relates to process an improved process for the preparation of azilsartan medoxomil. In particular, the field of invention relates to a process for purification of azilsartan medoxomil. More particularly, the invention relates to an improved process for preparation of azilsartan medoxomil and its pharmaceutically acceptable salts. | 04-24-2014 |
20140088127 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES - A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine. | 03-27-2014 |
20140057925 | AMORPHOUS FORM OF VILAZODONE HYDROCHLORIDE AND PROCESS FOR ITS PREPARATION - The present invention relates to an amorphous form of vilazodone hydrochloride and process for the preparation of amorphous form of vilazodone hydrochloride. The invention also relates to pharmaceutical compositions that include a therapeutically effective amount of the amorphous form of vilazodone hydrochloride and use of said compositions for the treatment of major depressive disorder (MDD). | 02-27-2014 |
20140051856 | NOVEL SALTS OF DPP-IV INHIBITOR - The present invention discloses new salts of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine i.e. gentisate, adipate and trifluoro acetic acid salts. The invention also describes the new. crystalline and amorphous forms of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine gentisate. The present invention also discloses novel crystalline salt form of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine hydrochloride and novel crystalline and amorphous salt forms of besylate and process for their preparation and isolation. | 02-20-2014 |
20140037725 | BILAYER PHARMACEUTICAL COMPOSITIONS OF NAPROXEN - The present invention is related to a bilayer pharmaceutical composition comprising naproxen or a pharmaceutically acceptable salt thereof. The present invention is particularly related to a bilayer pharmaceutical composition comprising an immediate release component and a controlled release component of naproxen or a pharmaceutically acceptable salt thereof and the process for preparation thereof. Moreover, the present invention is related to the treatment of rheumatoid arthritis, oesteoarthritis, ankylosing spondylitis, pain, primary dysmenorrhoea, acute tendinitis, bursitis and acute gout. | 02-06-2014 |
20140004189 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS MEMANTINE | 01-02-2014 |
20130338209 | TREATMENT FOR LIPODYSTROPHY - The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (Pis) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient. | 12-19-2013 |
20130337016 | METHOD FOR TREATMENT OF ACNE USING PHARMACEUTICAL COMPOSITIONS OF CLINDAMYCIN AND ADAPALENE - The present invention relates to a method for treating, reducing or preventing acne. In particular, the present invention relates to methods for reducing the total number, incidence and severity of acne lesions on the skin which includes both inflammatory and non-inflammatory lesions. Further, the invention relates to reducing the incidence and severity of adverse events resulting from topical application of anti-acne agents resulting in improvement of skin tone. The method includes administering a novel and stable topical anti-acne pharmaceutical composition. | 12-19-2013 |
20130330808 | NOVEL PROCESS FOR THE PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR - The present invention provides process of purification of tissue plasminogen activator (tPA) from a crude mixture or a partially purified mixture containing tPA protein and impurities by using hydrophobic interaction column chromatography, optionally in combination with ion exchange column chromatography. | 12-12-2013 |
20130295145 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING ETODOLAC - The present invention relates to stable pharmaceutical compositions comprising nano size droplets of etodolac or salts thereof along with other pharmaceutically acceptable excipients. These compositions exhibit greater permeability, and improved bioavailability leading to enhanced therapeutic activity. The invention also relates to processes for the preparation of such compositions. | 11-07-2013 |
20130289276 | PROCESS FOR PREPARING AN INTERMEDIATE OF SITAGLIPTIN VIA ENZYMATIC CONVERSION - The invention provides a process for preparing 3-hydroxy-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one (Formula I), into its racemic (R/S) form or any of its optically active (S) or (R) forms or enantiomeric excess mixture of any of the forms comprising:
| 10-31-2013 |
20130287825 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANO SIZE DROPLETS OF SKIN WHITENING AGENTS - The present invention relates to pharmaceutical compositions comprising mono size droplets of skin whitening agents or salts thereof. In particular, the present invention relates to a stable pharmaceutical composition comprising skin whitening agents or salts thereof along with other pharmaceutically acceptable excipients which possess substantially improved skin whitening effects and also exhibits greater skin permeability. The invention also relates to processes for the preparation of such compositions. | 10-31-2013 |
20130281366 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA - The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. | 10-24-2013 |
20130280308 | PHARMACEUTICAL COMPOSITIONS OF ANTI-ACNE AGENTS - The present invention relates to pharmaceutical compositions for treatment of acne. In particular, the present invention relates to stable pharmaceutical compositions for treatment of acne along with other pharmaceutically acceptable excipients. These compositions exhibit excellent stability, greater permeability, and enhanced therapeutic efficacy. The invention also relates to processes for the preparation of such compositions. | 10-24-2013 |
20130273172 | TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING NANODROPLETS FOR THE TREATMENT PSORIASIS - The present invention relates to stable topical pharmaceutical compositions for the treatment of psoriasis. Disclosed are in particular nonoemulsions comprising nano size droplets of one or more anti-psoriasis agents, e.g. clobetasol and/or salicylic acid. These compositions exhibit greater permeability, and improved bioavailability. The invention also relates to processes for the preparation of such compositions. | 10-17-2013 |
20130267560 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS OF DONEPEZIL - The present invention relates to sustained release pharmaceutical compositions of donepezil or pharmaceutically acceptable salts thereof. The compositions of the invention are stable and provide sustained therapeutically effective plasma levels over a twenty four hour period with reduced incidences of cholinergic side effects. The invention also relates to process of making such compositions. | 10-10-2013 |
20130266654 | METHOD FOR TREATMENT OF ACNE USING PHARMACEUTICAL COMPOSITIONS OF CLINDAMYCIN - The present invention relates to a method for treating, reducing or preventing acne. In particular, the present invention relates to methods for reducing the total number, incidence and severity of acne lesions on the skin which includes both inflammatory and non-inflammatory lesions. Further, the invention relates to reducing the incidence and severity of adverse events resulting from topical application of anti-acne agents resulting in improvement of skin tone. The method includes administering a novel and stable topical anti-acne pharmaceutical composition. | 10-10-2013 |
20130252980 | NOVEL GPR 119 AGONISTS - The present invention relates to novel GPR 119 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. | 09-26-2013 |
20130244280 | EXPRESSION VECTOR FOR HIGH LEVEL EXPRESSION OF RECOMBINANT PROTEINS - The present invention provides an expression vector for the production of proteins and peptides comprising a promoter operably linked to gene of interest, TPL and VA genes I and II, matrix attachment regions (MARs)/SARs, and antibiotic marker. The vector is transfected in suitable host cell. | 09-19-2013 |
20130243861 | PRESS-COATED TABLETS OF PREDNISONE - The present invention provides for press-coated tablets of prednisone comprising a core comprising prednisone and a coating around the core. The present invention particularly discloses thickness of the coating applied to core having a convex shape for chronotherapeutic use. The present invention also provides for a process for preparing a press-coated tablet of prednisone and a method for treating conditions or pathology, the symptoms of which occur early in the morning. | 09-19-2013 |
20130216617 | PHARMACEUTICAL COMPOSITIONS OF (R)-LANSOPRAZOLE - The present invention relates to stable pharmaceutical compositions of (R)-lansoprazole or pharmaceutically acceptable salts thereof and process of preparing the same. The invention particularly provides pharmaceutical compositions of optically active (R)-isomer of lansoprazole with at least two functional coating layers. | 08-22-2013 |
20130209553 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF PRAMIPEXOLE - The present invention discloses an extended release pharmaceutical composition of pramipexole or salts thereof comprising at least 40% w/w of hydrogenated castor oil, and one or more pharmaceutically acceptable excipients. | 08-15-2013 |
20130203668 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIPLATELET AGENTS AND AN ERYTHROPOIESIS STIMULATING AGENT - A composition comprising suitable anti-platelet agent/agents and the erythropoiesis stimulating agent for the treatment and improvement of kidney function is described. The combination also provides treatment and improvement in cardiovascular and bleeding related disorders. This composition shows synergistic interaction and significantly reduces the kidney damage caused by administration of erythropoiesis stimulating agents. Moreover the present composition normalizes the platelet reactivity and bleeding time in patients with chronic kidney disease. | 08-08-2013 |
20130197260 | PROCESSES FOR THE PREPARATION OF FESOTERODINE - The invention relates to improved process for the preparation of fesoterodine and its pharmaceutically acceptable salt, specifically fesoterodine fumarate of formula (1). The invention relates to solid state forms of a novel salt of fesoterodine and process for the preparation thereof. The invention also relates to highly pure fesoterodine fumarate substantially free of impurity X at RRT 1.37. The invention also provides solid particles of pure fesoterodine fumarate wherein 90 volume-percent of the particles (D90) have a size of higher than 200 microns. | 08-01-2013 |
20130190366 | SUBSTANTIALLY PURE SALTS OF FEBUXOSTAT AND PROCESSES FOR PREPARATION THEREOF - Substantially pure salts of febuxostat of Formula (IA): wherein Y is Na | 07-25-2013 |
20130172411 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE - The present invention relates to stable pharmaceutical compositions comprising fesoterodine or salts thereof. In particular, the invention relates to pharmaceutical compositions of fesoterodine which does not contain sugar alcohols. The invention also relates to processes for making such compositions and use thereof in treating patients with urinary incontinence. | 07-04-2013 |
20130150444 | MODIFIED RELEASE COMPOSITIONS OF MAGNESIUM VALPROATE - The present invention relates to a modified release pharmaceutical composition comprising therapeutically effective amounts of magnesium valproate and/or its pharmaceutically acceptable solvates or mixtures thereof and at least one rate controlling polymer. Rate controlling polymer is either hydrophilic or hydrophobic in nature. Mixture of the rate controlling material or more is also used to provide formulations of the present invention. | 06-13-2013 |
20130137695 | SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1-CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE-1 INHIBITORS - Disclosed are compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts. These compounds are suitable as Poly (ADP-ribose) polymerase-1 inhibitors (PARP-1 inhibitors). | 05-30-2013 |
20130095144 | PHARMACEUTICAL COMPOSITIONS OF SIROLIMUS - The present invention discloses a stable solid pharmaceutical matrix composition comprising sirolimus or pharmaceutically acceptable salts thereof along with one or more sugars. | 04-18-2013 |
20130059885 | Method For Preparation Of Pitavastatin and Pharmaceutical Acceptable Salts Thereof - The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium. | 03-07-2013 |
20120209022 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF - The invention relates to improved processes for the preparation of lacosamide. The invention also relates to a novel intermediate useful in the preparation of lacosamide. The invention also relates to process for the purification of lacosamide. | 08-16-2012 |
20120202988 | PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES - The invention relates to processes for the preparation of compound of CCI-779 having the Formula (I), which is useful as an antineoplastic agent. The invention further relates to certain novel intermediates useful in the preparation of compound of CCI-779 and processes for their preparation. The invention also relates to pharmaceutical compositions that include the compound of CCI-779, prepared according to the processes disclosed herein. | 08-09-2012 |
20120184544 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS - The present invention relates to substituted benzamide derivatives of the general Formula I and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, prodrugs, metabolites, and polymorphs and can be useful for treating disease states mediated by glucokinase. Compounds disclosed herein can be used for reducing blood glucose levels and for increasing insulin secretion for treating type II diabetes. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds, and their use. | 07-19-2012 |
20120149704 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS - The invention relates to disubstituted benzamide derivatives of the general Formula (I), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, prodrugs, metabolites and polymorphs. The invention also relates to processes for the preparation of the compounds of the invention, pharmaceutical compositions containing the compounds and to methods for treating type II diabetes using the compounds of the invention. | 06-14-2012 |
20120122905 | NOVEL GPR 119 AGONISTS - The present invention relates to novel GPR 119 agonists of the general Formula (I), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, stereoisomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of the invention, pharmaceutical compositions containing the compounds and to methods for treating one or both of diabetes and obesity using the compounds of the invention. The present invention is directed to G-protein coupled receptor (GPCR) agonists that are useful for the treatment of obesity, diabetes and related metabolic disorders. | 05-17-2012 |
20120121538 | COMBINED MEASLES-MALARIA VACCINE - A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several | 05-17-2012 |
20120115907 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN - The present invention relates to novel renin inhibitors of general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis. | 05-10-2012 |
20120077848 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES - A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine. | 03-29-2012 |
20120028996 | NOVEL OXIME DERIVATIVES - The present invention relates to novel oxime derivatives of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. | 02-02-2012 |
20120022102 | METHOD FOR PREPARATION OF PITAVASTATIN AND ITS PHARMACEUTICAL ACCEPTABLE SALTS THEREOF - The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium. | 01-26-2012 |
20110301200 | THYROID RECEPTOR LIGANDS - The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta (TR-Beta). Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them. | 12-08-2011 |
20110263623 | PROCESS FOR PREPARATION OF BOSENTAN - The present invention provides improved processes for preparing Bosentan. The present invention provides novel intermediates like 4,6-dihydroxy-5-(2-methoxy phenoxy)[2,2′]bipyrimidine of formula (II) and N-(6-Chloro-5-(2-ethoxyphenoxy)[2,2′-bipyrimidinyl]-4-t-butyl benzenesulfonamide cesium salt and process for preparation thereof. The invention also disclosed novel polymorphic form of the intermediates. | 10-27-2011 |
20110213149 | PROCESS FOR PREPARATION OF (2R)-4-OXO-4-[3- (TRIFLUOROMETHYL)-5,6-DIHYDRO [1,2,4]-TRIAZOLO[4,3-A]PYRAZIN- 7(8H)-YL]-L-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE & NEW IMPURITIES IN PREPARATION THEREOF - The present invention relates to synthesis of β-amino acid derivatives of formula (I) and its salts of formula (Ia) by a novel process. The process comprises the reduction of a protected or unprotected prochiral β-amino acrylic acid or derivative there of, by using borane containing reducing agents at atmospheric pressure. The resulting racemic β-amino compound is resolved to a pure stereoisomer of formula (I), specifically to (2R)-4-oxo-4-[3-Ctrifluoromethyl)-5,6-dihydrol[1,2,4]triazolo[4,3-alpyrazin-7(8H)-yl]-1-(2,4,4-trifluorophenyl)butan-2-amine. In an embodiment the invention disclosed polymorphic forms of formula (I), phosphate salt of formula (I) and also a Dibenzoyl-L-tartaric acid salt of formula (I). | 09-01-2011 |
20110212518 | EXPRESSION VECTOR AND METHODS OF PRODUCING HIGH LEVELS OF PROTEINS - A process for high expression of protein of interest using an expression vector. The process comprises at least the following regulatory elements: a) a CMV promoter, or its functional variants, b) an intron, c) TPL or its functional variants, d) VA genes or functional variants, and e) a bovine growth hormone polyadenylation sequence or functional variants. | 09-01-2011 |
20110065927 | PROCESS FOR PREPARING PURE ANASTROZOLE - The present invention discloses two new related substances (6) and (7) of Anastrozole synthesis from Q.A. Salt (5) as in Scheme-1 and purification procedures to get Anastrozole (1) free from (6) and (7). | 03-17-2011 |
20110065717 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS - The present invention relates to novel substituted sulfoximine derivatives of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. | 03-17-2011 |
20110021576 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES - A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine. | 01-27-2011 |
20110003846 | POLYMORPH AND AMORPHOUS FORM OF (S)-(+)-CLOPIDOGREL BISULFATE - The present invention relates to new polymorphs of S-(+)-Clopidogrel bisulfate and a process for preparing the same. | 01-06-2011 |
20100274014 | PROCESS FOR MANUFACTURING ROSUVASTATIN POTASSIUM AND CRYSTALLINE AND AMORPHOUS FORMS THEREOF - A process of manufacturing of Rosuvastatin Potassium of formula (I) | 10-28-2010 |
20100204268 | PROCESSES FOR PREPARING DIFFERENT FORMS OF (S)-(+)-CLOPIDOGREL BISULFATE - The invention provides improved processes for the preparation of hydrated form of (S)-(+)-Clopidogrel bisulfate as well as improved processes for the preparation of form-I and form-II of (S)-(+)-Clopidogrel bisulfate. | 08-12-2010 |
20100197923 | SALTS OF CLOPIDOGREL AND PROCESS FOR PREPARATION - Disclosed are new salts of Clopidogrel viz. Clopidogrel mesylate, Clopidogrel besylate and Clopidogrel tosylate, methods for their preparation and pharmaceutical compositions containing them and their use in medicine. | 08-05-2010 |
20100190999 | PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM - The present invention also provides the amorphous form of hemi-calcium salt of atorvastatin with high purity and processes for preparation thereof. | 07-29-2010 |
20100189746 | ADAPTATION OF PITMAN MOORE STRAIN OF RABIES VIRUS TO PRIMARY CHICK EMBRYO FIBROBLAST CELL CULTURES - The present invention relates to a process of adaptation of Pitman Moore strain of rabies virus to Primary chick fibroblast cells for the production of rabies vaccine. | 07-29-2010 |
20100145053 | MODIFIED RELEASE CLOPIDOGREL FORMULATION - A once daily dosage form comprising Clopidogrel or a salt of Clopidogrel equivalent to 50 mg to 150 mg Clopidogrel is disclosed. Said dosage form provides at least one of the following in vivo plasma profile of Clopidogrel selected from:
| 06-10-2010 |
20100081824 | Processes For the preparation of different forms of (S)-(+)-Clopidogrel besylate - Improved processes for the preparation of different forms of (S)-(+)-Clopidogrel besylate, pharmaceutical compositions containing them and their use in medicine. | 04-01-2010 |
20100074865 | FORMULATIONS OF PEG-INTERFERON ALPHA CONJUGATES - Lyophilized and stabilized formulations of PEG-Interferon alpha conjugates and the process for their preparation that reduces lyophilization cycle time and are more cost competitive. | 03-25-2010 |
20090275565 | Substituted aralkyl derivatives - The present invention relates to novel substituted aralkyl derivatives of the general formula (I) and (IIIa), their derivatives, their analogs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, pharmaceutical compositions containing them, use of these compounds in medicine and the intermediates involved in their preparation. | 11-05-2009 |
20090247765 | PROCESS FOR PREPARING PURE ANASTROZOLE - The present invention discloses two new related substances (6) and (7) of Anastrozole synthesis from Q. A. Salt (5) as in Scheme—1 and purification procedures to get Anastrozole (1) free from (6) and (7). | 10-01-2009 |
20090131314 | Thrombospondin-1 Derived Peptides and Treatment Methods - Treatments employing the matricellular protein thrombospondin-1 (TSP-I) and related compositions are disclosed for stabilizing atherosclerotic plaque and decreasing occurrence of plaque rupture events leading to, for example, myocardial infarction, stroke, and acute limb ischemia. Various peptides, including certain synthetic peptides, related to TSP-I are also disclosed. Such peptides have utility in stabilizing plaque in various contexts, including the disease states mentioned above. Some of these peptides include one or more sequences related to active sites of TSP-I for regulating, e.g., TGF-ss1 and MMP-9 activity. Experimental data show that a representative peptide provides a beneficial effect with systemic injection of the peptide. | 05-21-2009 |
20080300282 | Novel process to prepare pioglitazone via several novel intermediates - A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine. | 12-04-2008 |